ICR and Merck renew strategic alliance in discovery and development of innovative new small-molecule cancer drugs 22 Sep 2023 The Institute of Cancer Research, London, and science and technology company Merck have renewed their strategic alliance in the discovery and development of new cancer drugs. Find out more Show/Hide
‘Molecular glue degrader’ reaches cancer trial following ICR research programme 23 Feb 2023 The biotechnology company Monte Rosa Therapeutics – originally a spin-out from research at The Institute of Cancer Research, London – has announced that the first patient has received their ‘molecular glue degrader’ drug as part of a clinical trial in oncology. Find out more Show/Hide
ICR Discovery Club celebrates the second anniversary of the Centre for Cancer Drug Discovery 07 Nov 2022 Members of the ICR’s Discovery Club gathered at The Royal Society to hear about our new five-year research strategy and to mark two years since the opening of our pioneering Centre for Cancer Drug Discovery. Find out more Show/Hide
ICR and Cancer Research UK spinout company Monte Rosa Therapeutics raises USD96m in ‘Series B’ Financing 24 Sep 2020
ICR and Cancer Research UK spinout company Monte Rosa Therapeutics launches with library of anti-cancer compounds 10 Jun 2020